Regeneron Pharmaceuticals (REGN), a prominent biotech firm, underwent varying market sentiments as shown by recent events and statistics. Investigations on behalf of investors continue by law firms like Glancy Prongay & Murray LLP due to possible securities fraud. REGN's stocks declined in Q3 and its EV-to-Revenue ratio stands at 5.62 as of Nov 30, 2024. Holdings in Regeneron, by Glenmede Trust Co. and other investment firms, have been reduced or sold, while others like Townsquare Capital LLC and Bank of Montreal have increased or acquired shares. Several analysts have a bullish stance, despite insider sales suggesting hesitancy. Remarkably, REGN displays strong financial prospects, debt management capacities, and is named among the best Genomics and Biotech stocks. Controversially, Leerink analysts have downgraded REGN to Market Perform Hold following a negative preliminary injunction ruling on Eylea 2mg Biosimilar. On a positive note, Regeneron's financial and operating results for Q3 2024 indicated strong revenue growth, while Dupixent approvals signal breakthroughs in treatments for Smoker's Lung and Children's EoE disease.
Regeneron Pharmaceuticals REGN News Analytics from Mon, 03 Jun 2024 07:00:00 GMT to Sat, 30 Nov 2024 14:36:00 GMT -
Rating -1
- Innovation 6
- Information 7
- Rumor -3
